|
Taiwan Academic Institutional Repository >
Browse by Author
|
"denlinger cs"
Showing items 1-3 of 3 (1 Page(s) Totally) 1 View [10|25|50] records per page
國家衛生研究院 |
2021-10 |
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study
|
Valle, JW;Vogel, A;Denlinger, CS;He, AR;Bai, LY;Orlova, R;Van Cutsem, E;Adeva, J;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, H;Girvan, AC;Zhang, W;Liu, JG;Tang, CL;Ebert, PJ;Aggarwal, A;McNeely, SC;Moser, BA;Oliveira, JM;Carlesi, R;Walgren, RA;Oh, DY |
國家衛生研究院 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
|
Valle, JW;Bai, LY;Orlova, R;Van Cutsem, E;Alfonso, JA;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, HS;Denlinger, CS;Vogel, A;He, AR;Bousmans, N;Girvan, AC;Zhang, W;Walgren, RA;Carlesi, R;Oh, DY |
國家衛生研究院 |
2014-05 |
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad
|
Denlinger, CS;Sym, SJ;Bendell, JC;Alsina, M;Watkins, D;Chao, Y;Cubillo, A;Kunz, PL;Sun, WJ;Baeksgaard, L;Chen, LT;Horgan, K;Frye, S;Kudia, AJ;McDonagh, CF;Czibere, AG;Moyo, VM;Chibaudel, B;Bang, YJ |
Showing items 1-3 of 3 (1 Page(s) Totally) 1 View [10|25|50] records per page
|